Bempedoic Acid and Cardiovascular Outcomes in Statin …
Mar 4, 2023 · The risk of death from cardiovascular causes, nonfatal stroke, or nonfatal myocardial infarction (the first key secondary end point) was 15% lower with bempedoic acid …
Nexletol: Uses, Dosage, Side Effects, Warnings - Drugs.com
Aug 5, 2024 · Nexletol (bempedoic acid) is an oral tablet for high cholesterol that may be used to lower the risk of heart attack and heart procedures (for example stent placement or bypass …
Nexletol shows CLEAR benefit in cardiovascular outcome trial
3 days ago · New data for Esperion’s cholesterol lowering daily pill Nexletol, used when statins are not working in people at risk of a heart attack, could inject some momentum into the drug’s …
In Brief: Cardiovascular Outcomes with Bempedoic Acid (Nexletol)
CONCLUSION ― In one large clinical trial in statinintolerant patients who had or were at high-risk for cardiovascular disease, the oral adenosine triphosphate- citrate lyase (ACL) inhibitor …
Bempedoic Acid: A Review in Cardiovascular Risk Reduction in …
Jan 23, 2025 · Abstract Oral bempedoic acid (NEXLETOL ® in the USA; Nilemdo ® in the EU) and the fixed dose combination (FDC) of bempedoic acid/ezetimibe (NEXLIZET ® in the USA; …
NEXLIZET® & NEXLETOL® CLEAR Outcomes Trial Information
The most common adverse reactions in the cardiovascular outcomes trial for bempedoic acid, a component of NEXLIZET and NEXLETOL, at an incidence of ≥2% and 0.5% greater than …
CLEAR Outcomes: Bempedoic Acid Reduces Cardiovascular …
Mar 4, 2023 · The non-statin lipid-lowering medication bempedoic acid (Nexletol®) has demonstrated a significant reduction in the risk of cardiovascular events in a large outcomes …
Exploring Recent Guideline Updates on the Management of …
5 days ago · The results showed that the study participants randomly assigned to Nexletol were 13% less likely to have a major cardiovascular event (defined as death from cardiovascular …
U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® …
Mar 22, 2024 · U.S. FDA approves broad new labels for NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets to prevent heart attacks and …
U.S. FDA Approves Broad New Labels for NEXLETOL® and …
ANN ARBOR, Mich., March 22, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad …